$AAPG News

Ascentage Highlights Tumor Response Data in Pediatric Cancer Study

Ascentage Highlights Leukemia Treatment Data, Expands Global Development Efforts

Reported Sunday, Ascentage Pharma Presents Preclinical Data At AACR 2026 Supporting Olverembatinib Combinations In Endometrial Carcinoma And Mantle Cell Lymphoma Alongside APG-2449 And APG-5918

Reported Sunday, Ascentage Pharma Presents Preclinical Data At AACR 2026 Supporting Olverembatinib Combinations In Endometrial Carcinoma And Mantle Cell Lymphoma Alongside APG-2449 And APG-5918

BTIG Reiterates Buy on Ascentage Pharma Group, Maintains $48 Price Target

BTIG Assumes Ascentage Pharma Group at Buy, Announces Price Target of $48

Ascentage Pharma Group International (AAPG) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript

Reported Earlier, Ascentage Pharma Secures IND Approval In China For APG-3288 BTK-Targeted Protein Degrader

Ascentage Pharma Group International (AAPG) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow

Is Ascentage Pharma Group (SEHK:6855) Price Swings Creating A Valuation Opportunity Now

Reported Earlier, Ascentage Pharma Highlights Dual-Engine Growth And Global Pipeline Expansion During J.P. Morgan Healthcare Conference Presentation

Ascentage Pharma Group International (AAPG) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Ascentage: Partnership With Takeda Going Well

Ascentage Pharma B-Cell Cancer Candidate Receives FDA IND Clearance

Reported Earlier, Ascentage Pharma Secures FDA IND Clearance For BTK Degrader APG-3288 Advancing Global Phase I Development In B Cell Malignancies

Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288

Ascentage Pharma to Present at 44th Annual J.P. Morgan Healthcare Conference

Is Ascentage Pharma Group International Still Attractive After Its Big Multi Year Price Surge?

Reported Earlier, Ascentage Pharma Presents First Phase III POLARIS-1 Dataset At ASH 2025 Showing Best MRD Negativity 66.0% And MRD-Negative CR 64.2% In Newly Diagnosed Ph+ ALL

Reported Earlier, Ascentage Pharma Presents Updated Olverembatinib Data At ASH 2025 Showing 76.7% CCyR And 60% MMR In Second-Line CML-CP